期刊
MOLECULAR AND CELLULAR BIOLOGY
卷 29, 期 2, 页码 547-558出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/MCB.00329-08
关键词
-
资金
- Canadian Institutes of Health Research [MOP14700, MT12121]
- National Cancer Institute of Canada
- National Institutes of Health [AG025688]
- Canadian Diabetes Association
- Royal Victoria Hospital Research Institute of McGill University
- Fonds de la recherche en sante du Quebec
p27(Kip1) is a cyclin-dependent kinase inhibitor that regulates the G(1)/S transition. Increased degradation of p27(Kip1) is associated with cellular transformation. Previous work demonstrated that the ubiquitin ligases KPC1/KPC2 and SCFSkp2 ubiquitinate p27(Kip1) in G(1) and early S, respectively. The regulation of these ligases remains unclear. We report here that the USP19 deubiquitinating enzyme interacts with and stabilizes KPC1, thereby modulating p27(Kip1) levels and cell proliferation. Cells depleted of USP19 by RNA interference exhibited an inhibition of cell proliferation, progressing more slowly from G(0)/G(1) to S phase, and accumulated p27(Kip1). This increase in p27(Kip1) was associated with normal levels of Skp2 but reduced levels of KPC1. The overexpression of KPC1 or the use of p27(-/-) cells inhibited significantly the growth defect observed upon USP19 depletion. KPC1 was ubiquitinated in vivo and stabilized by proteasome inhibitors and by overexpression of USP19, and it also coimmunoprecipitated with USP19. Our results identify USP19 as the first deubiquitinating enzyme that regulates the stability of a cyclin- dependent kinase inhibitor and demonstrate that progression through G(1) to S phase is, like the metaphase- anaphase transition, controlled in a hierarchical, multilayered fashion.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据